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Successful immunotherapy of established B16 mela-
noma metastases in C57BL/6 mice can be achieved by 
antibody-targeted interleukin-2 administration. This 
therapeutic effect is accompanied in approximately 
20% of the animals by induction of a population of 
lym.phocytes that migrates to and substantially dis-
rupts the cytoarchitecture of the skin, which results 
in progressive alopecia. The histologic changes asso-
ciated with the hair loss, i.e., peri-, and intrafollicu-
lar inflammatory infiltrates consisting of both acti-
vated CD4+ and CD8+ T cells, as well as expression 
of major histocompatibility complex class I antigens 
on subinfundibular follicle epithelium, are similar to 
those observed in human alopecia areata. Further-
A II hair growth is cyclical with alternating periods of follicle growth (anagen) and rest (telogen). The transition from growth to rest (catagen) involves regression, carefully controlled to prevent complete follicle des truction (Orfanos and Happle, 1990; 
Hardy, 1992). The mechanisms involved in the regulation of the 
hair cycle remain elusive. Several recent studies, however, have 
suggested that hair growth may be controll ed by the immune 
system (Paus and Link, t 988; Westgate el ai, 1991). This involve-
ment is most obvious in alopecia areata (Paus e/ ai, 1994a). 
Alopecia areata is a common disease in humans that is chara c-
terized by acute onset of focal, diffuse, or both forms of hair loss 
(Orfanos and Happle, 1990). The ea rliest histo logic signs of 
alopecia areata are peri- and intra follicular inflammatory infiltrates 
consisting of both activated CD4+ and CD8 + T ce ll s, as well as 
macrophages and some Langerhans cells (Khoury cI ai, 1988; 
MacDonald-Hull e/ ai, 1991; Paus e/ ai, 1994a). In acute les ions, 
intrabulbar inflammatory cells can be detected in close proximity to 
hair matrix m elanocytes. Thjs infiltrate is essential for alopecia 
area ta, and only an agen folJjcles are affected. This cellular attack 
terrrlinates anagen prematurely and expedites the follicle into 
catagen, often with signs of follicle dystrophy, but, typically, there 
is no follicle destruction (Tobin e/ ai, 1990) . 
T he availability of recombinant immunomodulatory cytokjnes in 
pham1acologic quantities and the ability to manipulate these pro-
teins at the genetic level Ilave allowed testing of the effects of these 
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more, the alopecic phenotype can be transmitted 
horizontally by passive transfer of lymphocytes from 
treated animals to naive mice. Since lymphocytes 
from treated animals either lacking or displaying 
signs of alopecia are able to transmit these pheno-
typic changes to a similar percentage of naive ani-
mals, the initiation of alopecia seems to be dependent 
on the coincidence of at least two different events: 
the presence of specific lymphocyte populations as 
well as specific features of the skin disclosing a 
target for these cells. Key words: antibody-targeted 
IL-2Itllel'apylalopecic pllenotypell,orizolttal tl'attsttlissiolll 
ttlltl'ille melanoma.] Invest Del'matoI107:627-632, 1996 
molecul es on the host response to cancer in an empmc fashion 
(Maas ef ai, 1993) . It became obvious that the systemic administra-
tion of cytokjnes to activate immunologic responses fails to account 
for the fact that these molecules maint;un specificity partially through 
their paracrine function (pat'doll, 1995). Physiologically, systemic 
conceno'ations of most cytokines during an immunologic response are 
orders of magnitude below the dissociation constant of their receptor, 
thereby allowing them to avoid generalized effects (paul and Seder, 
1994). A therapeutic approach that confonllS with the paracrine nature 
of cytokines is the ex '';'10 genetic modification of tumor cells that 
allows ill si/II expression (Dranoff and Mulligan, 1995; Pardoll, 1995). 
Despite the highly encouragin g preclinical data obtained with this 
approach, the feasibiljty of its broad clinical application as a cancer 
therapy appears limited by its patient-specific nature. 
We recently established an altemative approach for cancer therapy 
tllat combines effective local concellO~atiolls of cytokjnes in the tumor 
microenvironment, low systemic toxicity, and a technically simple 
modus operandi (Becker e/ ai, 1996b). Tlus goal was achieved by 
construction of fusion proteins consisting of tumor-specific monoclo-
nal antibodies and cytokines, which employed the U1uque targeting 
ability of antibodies to direct cytokines to tlle tumor site (Gillies ef ai, 
1992). Antibody-targeted interleukin-2 (lL-2) tllerapy is able to erad-
icate establjshed pulmonary, hepatic, and subcutaneous melatloma 
metastases in a syngeneic mu6ne tumor model (Becker e/ ai, 1996a,c). 
Immunohistochemical atlalysis, ill IIillo depletion studies, and tlle use of 
alumals with defined inullU1le defects demonso'ated that this erarnca-
tion of tumor metastases is mediated by host inlJlllU1e cells, particularly 
CD8 + T cells. Here, we report tl13t such successfitl immunotherapy of 
melanoma in C57BL/6 mice is accompanied in approximately 20% of 
the animals by induction of a progressive alopecia and that tlljS 
phenotype can be transmitted horizontally by passive transfer of 
lymphocytes. 
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MATERJALS AND M ETHODS 
Cell Lines, AniDlals, and Reagents The ITIurinc TTlcian0 l11:t cell Hn es , 
B16 and B78-D14, have been described prev iously (Haraguchi el ,,1 , 1994 ) . 
B78-D14 was derived from B16 m elanoma ce ll s by do uble transfection with 
genes coding for {3-1 ,4 - N-acetylga lactosaminyltransferase and a-2 ,8- sialyl-
tra nsferase inducing a constitutive express ion of gangliosides GD2 and 
GD3 . 
C57BLl6j, C57 BLl6j be(~c/I)c(~e and C57 BLl6j scid/scid mice were 
obtained fi'om Jackson Laboratory (Bar Harbor, ME) at the age of 4-6 wk. 
These animals were ho used under specific pathogen-fi'ce conditions, and all 
experiments were performed according to N atio nal Institute of H ea lth 
guidelines for care and usc of laboratory animals. 
The antibody-IL-2 fu sion proteins, ch14. 18-1 L2 and ch225-IL2, were 
constructed by fu sion of a syntheti c sequence coding for human IL-2 to the 
ca rboxyl end of the human Cy1 gene as described previously (G illies cl nl, 
1992). The resu lting express ion vectors were introduced into Sp2/0-Ag14 
cells and se lected in Dulbecco's modified Eagle's medium supplemented 
with 10'X, fetal bovine se rum and 100 nM methotrexate . T he fu sion protein 
ch1 4.18- IL2 reacts w ith the ganglios ide GD2, and ch225-IL2 reacts with the 
human epidermal growth fa ctor receptor (Becker ct nl , 1996b). 
TUl110r Models and Therapeutic Protocols To induce experimenta l 
lung m etastases, single cell suspension of 5 X I 0" tumo r cell s, in 500 ILl of 
phosphate-buffered sa line (PBS) /O .l % bovine se rum albumin , was injected 
into the lateral tail vein . After 7 d, micro metastases were present and 
disseminated throughout the lung, in vading pu lmonary alveoli . 
Experimental hepatic metastases were induced as described previously 
(Becker el nl, 1996). T umor ce ll s (2.5 X 10") were injected in 1 00 ILl of 
R.PMI 1640 with a 27-gauge needle beneath the splenic capsule over a 
period of 60 s. T he needle was removed after an addi tional 60 s, fo llowed 
by ligation of the splenic pedicle with a 4-0 silk suture and the remova l of 
the spleen . 
T reatment of mice was sta rted 1 wk after tumor cell inoculation by iv 
administration of 8 ILg of antibody-IL-2 fus ion protein for 7 d once a day. 
Control animals received either phosphate-buffered saline alone or the 
combina tio n of equimolar amounts of recombinant IL-2 (24,000 IU) and 
the parental antibody (8 ILg) as compared to the fus ion protein. 
Il11l11unohistology Frozen sections were fi xed in cold acetone for 10 
min fo llowed by removal of endogenous peroxidase with 0.03% H20 2 and 
blocking of co llagenous elements with 10'% species-specific serum in 1 % 
bovine serum albumin / PBS . T he antibodies were then overlaid onto seri al 
sectio ns 'at predetermined di lu tions (usua lly 20 ILg per ml) and incubated in 
a humid chamber for 20 min . With PBS washes between every step, a 
biotinylated link antibody was appiied for 10 min foll owed by an enzyme, 
i. e., e ither peroxidase or alkaline phosphatasc, linked to streptavidin for 10 
min. After an additional wash , the substra te was added and the slides were 
incubated in the dark for 20 min. Biopsies were ana lyzed fi'om both 
transverse and vertical sections (Elston el nl, 1995). After a wash in PBS, the 
slides were counter stained , mounted , and viewed using an Olympus BH 2 
microscope (Olympus Corp., Lake Success, NY) with photographic capa-
bilities. 
Passive Transfer of Lymphocytes Single-cell suspensions were pre-
pared by mincing fi'eshly resected spleens into small pieces and passing thcm 
through a steel sieve. After being washed twice with Hanks' balanced sa lt 
so lution, viable ce lls were separated on a Fico ll / H ypaque gradient (Nyco-
prep animal , N ycomed Pharma, Oslo, N orway) at 600 X .g for 20 min , 
washed twice, counted, and resuspended at a concentration of3 X 107 ce lls 
pcr tnl in PBS cont;:lining 0.1°ft) bovine se runl albulnin. Cc1l suspensions 
were injected into the lateral tai l vein over a period of 60 s. To prevent 
pulmonary embolism caused by injection of cell s, mice were anesthetized by 
halothane inhala tion, and the tumor ce lls were administered in three 
fi'actions of 1 X 107 cells with 2 h between injections. 
RESULTS 
T -Cell-Mediated Eradication of Melanoma Metastases In-
duced by Antibody-IL-2 Fusion Proteins B16 melanoma 
cell s that had been transfected with genes coding for {3-1,4-N-
acetylga lactosaminyltransferase and a -2,8-sia ly ltransferase, result-
ing in a constitutive expression of the gangliosides GD2, form 
experimental pulmonary and h epatic metastases in syngene ic hosts. 
Mice bearing such tumors can b e successfully treated with an 
antibo dy-cytokine fusion protein (ch14 .18-IL2) that combines th e 
ta rgeting abili ty of th e monoclonal antibody ch1 4.18 to the gangli-
oside GD2 with the mu ltifunctional activ ity of IL-2 . Daily iv 
injec tions o f 8 /Lg of ch14 .18-IL2 fusion protein for 7 d induce a 
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Table I. Incidence of Alopecia in Melanoma-Bearing 
C57BLl6 Mice Following Immunotherapy 
Pulmonary Metastases 
Expcrinlc ll t T herapy" Incidence O nse t" Type' 
PBS 0/16 
r1 L2 and ch1 4.18 0/16 
ch14 .18-IL2 4/16 21 FS head, spreads 
to dorsa I trunk 
27 3 FS the dorsal 
trunk 
28 DifFuse 
33 Initial FS head , 
spreads to be 
diffuse 
2 PBS 0/8 
r1L2 and ch1 4.18 0/8 
ch14 .18- IL2 2/8 14 3 FS head and 
trunk 
21 Diffuse 
3 PBS 0/8 
ch225-IL2 0/8 
chI 4 .1 8-IL2 218 17 Diffuse 
21 3 FS head, flank 
and ventra.l 
trunk 
4 ch1 4.18-IL2 7/36 18 DifFuse 
18 4 FS trunk and 
flanks, spread 
to be diffuse 
21 FS head 
21 Diffuse 
21 3 FS flanks and 
back 
24 FS head 
25 Diffuse 
Hepatic Metastases 
5 PBS 0/16 
r1L2 and ch14 .18 0/16 
chI4 .18-IL2 5/16 14 Start at operaton 
site , diffuse 
14 Start at operation 
site, djfFuse 
16 Diffuse 
18 Start at operation 
si te, diffuse 
21 FS head , trunk 
and flanks 
, 'I Experimelltal pulmonary and hepatic meta stases were induced by iv injection of 5 
X '10" o r intraspcn.ic injectio n of2.5 X 10(' B7S-Dt 4 cells. respective ly. TrcatJllcnr was 
st<lrtcd ·1 week there:lfte r and consisted of d;li ly iv administration of PBS. 8 j.tg chimeric 
monoclottal :l lltibody ch1 4. 18 and 24.000 lU rccombinant IL2. or 8 j.tg of c it Iter the 
nonspecific fus ion pro tein c1 l225- IL2 or the tumor-specifi c fu sion protein cll t 4.1S-1 L2 
as i11dicated for 7 consecutjve days. 
/. Days after start of therapy. 
( FS. foca l site. 
comple te regression of m e tastases in more than 90% of the animals. 
Se veral lines of evidence, i.e ., immunohistology, ;11 11;110 d eple tion 
studies, and cytotoxicity assays , indicated that tllis antitumo r effect 
is largely d e pendent on CD8 + T cells (Bec ke r et nl, 1996a,c) . 
Successful Immunotherapy Is Accompanied by Alopecia 
A dramatic side effect of tllis T -cell-mediated eradication of 
m e lanoma metastases is the developme nt of a progressive alopecia 
in 23% of the treated animals (Table I and Fig 1). All C57BL/6 
mice that subseque ntly deve loped a lopec ia had a normal-appearing 
coat of hair prior to the start o f therapy. T h e onset of h air loss 
ranged from 14 to 33 days after start of therapy. Most affected 
an imals initially displayed focal or l11ultifocal alopec ia ; a frequently 
observed location was the head above the skull (Fig 1A). Progress-
VOL. 107, NO.4 OCTOBER 1996 IMMU N OTH ERAPY AND ALOPECIA 629 
, 1111111111 111111111111111 " 1 " " II " 111/ " III " II jill II MElRlC o (em) 1 2 3 4 5 
A 
Figure 1. Immunotherapy induced alopecia. (A) Focal alopecic lesion above the skull. (B) Generalized diffuse hair loss on the dorsa l trunk and regrowth 
of hair followed by intrales ional injection (-» of triamcinolone acetonide . 
ing from these focal sites, a generalized alopecia evolved over a 
period of weeks in half of these animals , [n several mice tlus 
generalized alopecia was the fust clinica l sign . A widespread 
thinning of the pelage was more common than complete balding 
(Fig lB). As the skin becom es increasingly affected, it loses 
suppleness and elasticity. Furthermore, a pi tyriasiform scaling is 
present in the affected areas. 
The incidence of alopecia is strictly dependent on the immuno-
therap eutic effect of the fusion protein and cannot be considered as 
a side effect of fusion protein itself, because no dermatologic 
changes were observed in naIve mice receiving escalating doses of 
the fusion protein in toxicity studies. Specifically, 48 C57BL/6 mice 
received dai ly iv injection of various amounts of ch1 4. 18-IL2 
ranging between 8 and 256 JLg each over a period of 7 d . None of 
these animals developed signs of alopecia witllin an o bserva tion 
period of 8 wk. Histologic examination of skin biopsies obtained 
from animals treated with 16 JLg of ch14.1 8-IL2 28 days after 
cessation of therapy disclosed no abno rmalities (data not shown) . 
Furthermore, the incidence of alopecia calmot be attributed to the 
mere presence of B7S-D14 tumors, because none of the animals 
sulfenng from pulmonary or hepatic metastases that were treated 
with either PBS alone or the combination of recombinant IL2 and 
the c h14.1 8 antibody developed dermatologic abnormalities within 
their remaining life span (mean survival 44 and 51 d, respectively) 
(Becker et ai, 1996a). The association of hair loss with a successful 
immunotherapy was further confirmed by the lack o f its occurrence 
in melanoma-bearing mice receiving non-tumor- specific fusion 
protein (Table I, Exp. 3) . 
Intralesional Injection of Triamcinolone Acetonide In-
duced Regrowth of Hair In the truncal skin of mice, all 
melanocytes reside in hair follicles, and m elanogenesis occurs 
exclusively in anagen follicles. Thus, in pigmented mice such as 
C57BL/6, anagen can be easily distinguished from telogen by 
simple observation of skin color: pink denotes telogen, gray to 
black corresponds to anagen IV-VI. The skin of affec ted animals 
appeared grayish to black prior to the onset of alopecia, indicating 
the presence of hair follicles in active anagen. During the course of 
the effluvium the skin turned pink, which was more obvious in 
areas of alopecia. These chan ges of skin coloration, how ever, were 
not consistently observed in all affected animals. Afte r receiving 
intralesional injections of triamcinolone acetonide (two injections 
of 250 mg separated by 1 wk) mice primarily showed changes in 
skin pigmentation fI'om pale pink to dark gray followed by re-
growth of hair (Fig lB) . 
CD4+ and CD8+ T Cells Are Present in Alopecic Lesions 
Histologic examination of affected skin from alopecic animals 
reveals atrophy and loss of hair follicles, a thickening of the 
epidermis, and the presence of lymphoid infiltrates in the dermis. 
The mononuclear cell infiltrate was present around and within tlle 
follicular epithelium in the bulbar regions and in and along tile hair 
follicle epithelium up to the level of the sebaceous gland. Immu-
nolustologic staining Witll an anti-CD45 antibody (clone 30F11.1, 
rat IgG2b, K) on skin biopsies from both affected and normal naIve 
animals confirmed the marked infiltration with leukocytes in nUce 
suffering from alopecia (Fig 2A,B). Further characterization re-
vealed that tlus inflammatory infil trate consis ts of both CDS + 
(clone 53-6.7, rat IgG2al and CD4 + (clone H129.19, rat IgG2al T 
cells (Fig 2C-F) . 
Loss of Major Histocompatibility Complex (MHC) Class I 
'Negativity' of Hair Follicles in Alopecic Lesions Tissues 
tllat are prone to be involved in autoimmunity, such as brain, 
pancreas, thyroid, and testicles, normally lack detectable am ounts 
of both MHC class I and class II antigens (Billingham 3lld Silvers, 
1971; Natali e/ ai, 1984) . Paus el ai, dem onstra ted that in C57BL/6 
mice, MHC class I expression is absent in tlle matrix and inner root 
sheet of anagen hair follicles and the dermaJ papillae are MHC class 
I negative during catagen and telogen (Paus e/ ai, 1994c). Tlus 
MHC class I 'negativiry' is lost in the hair follicles of human 
alopecia areata lesions (Brocker et ai, 1987). Antibodies against 
MHC class I H_2Kb I h-2Db (clone 28-S- 6, C3 H IgG2a , K) strongly 
stained epidermal keratinocytes and the epi thelium of infundibular 
fo llicles in biopsies from normal and affected mice. In nonalopecic 
animals of the therapy group, the subinfill1dibular fo llicle epithe-
lium and the hair m atrix showed , at best, a fa int staining (Fig 3A). 
In contrast, les ionallperilesional biopsies from animals suffering 
fro m alopecia revealed a strong homogeneous staining of the hair 
follicle below the level of the sebaceous gland (Fig 3B) . Interest-
ingly, biopsies of normal skin obtained fro m mice that suffered from 
localized immunotherapy-associated alopecia exlubited tile same 
expression ofH-2Kb I h-2Db as nonalopecic animals and also lacked 
tile perifollicular infiltration with mononuclear cells. Expression of 
MHC class II I-A b antigens (clone 25-9- 17, C3H IgG2a , K) in 
normal skin was confined to a few intraepidermal dendritic cells, as 
previously dem onstrated (Brocker e/ nl, 1987) . In animals sufferin g 
from alopecia, reactivity w ith the anti-I-Ab antibody could also be 
demonstr ated for the majority of infiltratin g mononuclear cells, 
indicating the activated state of these cells (data not shown). 
Anagen Hair Follicles Arc Predominant in Alopecic Lesions 
In order to dissect w hat distinguishes animals developing alopecia 
after fusion protein therapy from those that did n'ot, the predomi-
nant hair cycle stage of such animals was determined by morpho-
metric quantitation. For each gro up an average of 50 follicl es 
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Figurc· Z. Inflammatory infiltratc in alopccic lcsions. Immunohisto-
logic staining of sIGn biopsies obtained from normal mice (A) and an imals 
sufFe l·ing from alopecia (B) with an anti-CD45 monoclonal antibody. 
Characterization of the inflammatory in fi ltrate fo r reactivity with anti-CDS 
(C,D) and anti-CD4 (E,F) monoclonal antibodies on vertical (C,E) and 
transverse (D,F) sections of sIGn biopsies; scale bars: (A,B) 100 J-Lm; (C-F) 25 
J-Lnl. 
d eriv ed from four mice were analyzed using established hair cycle 
classification criteria (Straile el 11/, 1961; Paus el 11/, 1994b). T his 
analysis revealed that m ost hair fo llicl es in the skin of no n alopecic 
tes t animals were in telogen (telogen, 45; anagen , 3; dystrophic, 4), 
w hereas the fo llicles in the skin of alopecic animals displ ayed a 
more diverse pattem , which was do minated by dys trophic fo llicles 
or such in anagen (te logen , 12; anagen, 28; dystro phi c, 21). 
Infectious Diseases Are Not Involved in Immunotherapy-
Induced Alopecia Several infectious agents are well known 
ca uses of fo llicular and perifollicular inflammation , w hich can result 
in alopecia. In order to rule out an infectious di sease as an etiologic 
facto r for the observed immunotherapy-associated alopecia, skin 
biopsies, as well as uprooted hair from alopecic and bordering areas, 
were cultured for bacteria and fun gi. In One of seven animals 
Sll1phylococCIIs spp. was isolated from an uprooted hair. N one of the 
anim als showed serologic signs for other common mouse pathogens 
(Wagner et 11 /,1991) . 
The Alopecic Phenotype Can Be Transmitted Horizontally 
by Passive Transfer of Lymphocytes To determin e the rele-
vance of NK and T cell s in this form of alopecia , tumors were 
indu ced in either NK or T-cell-deficient mi ce, followed by 
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Figure 3. MHC class I expression. Immunohistologic staining of skin 
obtained from normal mice (A) or animals suffe ring fi·om alopecia (B) with 
an anti_H_2Kh /h_2Dh MHC class I antibody; scale bar, 100 J-Lm. . 
treatment w ith ch14 .18-IL2. Three of 16 NK cell-deficient 
C56BL/6 beige/beige mice develo ped alopecia afte r th erapy. In the 
case ofT-cell-deficient C56BL/6 scid/scid mice (n = 16), there was 
no incidence of alopecia . It should be noted, however, that 
successful treatm en t of m elanoma m e tas tases could not be achieved 
in these animals either. 
T h ese observations suggest that the o bserved alopecia may be 
caused by autoreactive lymphocytes, particularly T cells , that were 
generated during immunotherapy . To test this notion, we trans-
ferred lymphocytes £i·om su ccessfully treated C57BL/6 mice dis-
playin g either alopecia or no phenotypic changes to normal nalve 
mice (3 X 107 cells per mouse) . FollowiJ1g this procedure, a similar 
percen tage of recipients developed alopecia as compared to those 
receiving the initial treatm ent (8 of 36 recipients). T he hair loss 
developed w ithin 1 wk (ran ge 5-7 days) after transfer of lympho-
cytes. In te restingly, the dermatologic predicament of the donor had 
no influence on the subsequent development of alopecia in the 
recipient, inasmuch as transfer of lymph ocytes of alo pecic as well as 
no n alopecic dono rs ca used alo pecia in recipients (2 of8 and 60f28, 
respective ly) . T herefore, the initial immunotherapy induces only 
one condition required fo r lymphocyte-mediated hair loss; other 
conditio ns, e .g., antigen expression, cri tica lly influ ence the later 
outcome. 
D ISCUSSION 
Success ful immunotherapy of established m e lanoma m e tastases can 
be achieved by antibody- targeted IL-2 admin istration (Becker et 11/, 
1996a- c). In approximately 20'Vo of such treated animals, the 
therape utic effect is accompani ed by progressive alopecia . The 
in cidence of alopecia was co nfin ed to immunocompetent mice, and 
the phenotypic changes were histologicall y characterized by an 
inflammatory in fi ltrate, in cluding CD8 + T cells. Furthermore, 
alopecia could be transmi tted horizonta lly by pass ive transfer of 
lymphocytes from treated animals to na·ive mice . T he induction of 
alopecia by the fu sio n prote in itself seem s unli kely beca use none of 
the naIve an imals used in toxicity studies develop ed this condition. 
T he observed histologic changes, i.e., pe ri- , and intrafoUicuiar 
inflammatory infiltra tes consisting of both activated CD4 + and 
CD8 + T cell s and express ion of MHC class r antigens on subin-
fundibular follicl e epithelium, are simil ar to those observed in 
human alopecia areata (Brocker et 11 /, 1987; Khoury el 11/, 1988). 
Several authors proposed the hypothesis that alopecia areata may 
refl ec t an unexplored form of au toimmunity (M essenger and 
Bleehen, 1984; Slominski and PallS, 1993; Paus el 11/, 1994a). 
Accordin g to this hypothesis, the ini tiation of alopecia is based on 
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the coincidence of severa l events predisposing to disease develop-
ment: (i) the breakdown of MHC class I- ' nega tivity' of the anagen 
hair bulb, (ii) the exposure of 3utoantigens by MHC class I 
molecules, and (iii) the presence of autoreactive T cells that 
recognize autoantigens and displa y cytotoxic activity. 
T he excl usive involvement of mclanogenica lly active anagen 
follicles, the highel' in cidence in bl ack- haired individuals, and the 
association with vit ili go suggest the follicular m elanocyte as an 
important etiologic facto r in alopecia areata (Messenger and Blee-
hen, 1984). The source for possible autoantigenic peptides are 
unknown but might include e ither nonspecifi c membrane and 
extramelanosomal cytoplasmic proteins o r, as an attractive alte rna-
tive, m elanocyte-specific m elanogenesis-related proteins, e.g., ty-
rosinase, b-Iocus protein (TRP-l), dihydroxyphenylalaninechrome 
cautomerase (TRP-2), and Pmel17 (Kwon, 1993). For most of the 
latter, it has been demonstrated that they ca n be processed in 
melanoma cell s to be presented to autologous T lymphocytes by 
MHC class lor class H molecules (Kawakami el nl, 1994; Boon el nl, 
1995; Chen el nl, 1995; Wang el nl, 1995). 
Patients with melan oma have been observed to develop vitiligo 
or depigmented spots on the skin (Nordlund el nl, 1983). Melanoma 
and vitiligo were also found associated in other mammalian species, 
e.g . , the Sinclair swin e and a variety of horses (Lerner and Cage, 
1973; Millikan el nl, 1973). The association with vitiligo presages a 
good prognosis for patients with melanoma (Nordlund el nl, 1983). 
Furthermore, the induction of vitiligo-like depigmentations follow-
ing immunotherapy with IL-2 and interferon-a has been reported 
in melanoma patients (Richards el nl, 1992). T he exact mechani sm 
for m elanocyte destru ction in vitiligo has not been conclusively 
identified thu s far. Recent reports, however, suggest a role for 
CD4+ and CD8+ T lymphocytes as effector cells and tyrosinase as 
principal autoanti gen (Badri eI nl, 1993; Song ef nl, 1994). 
It is conceivable that autoreactive T cells recognizing melano-
genesis-related antigens are induced by the applied immunotherapy 
designed to eradicate m elanoma metastases. We ha ve previously 
shown that tumor regression induced by therapy with tumor-
speci fic antibody-IL-2 fu sion proteins is m ediated by CD8+ T cells 
(Becker el nl, 1996a,c). H ere, we demonstrate not only the 
infiltration ofCD8 + T cell s into the skin of alopecic areas, but also 
that trus phenotype can be transmitted horizontall y by pass ive 
transfer of mononuclear cells . The relevance of T-cell subsets was 
confirmed, beca use the inciden ce of alopecia was not altered in NK 
cell-deficient mice but completely absent in animals deficient in T 
cells. Preliminary studies further delineate CD8+ cytotoxic T cell s 
as the relevant effector cell population, inasmu ch as passive transfer 
of CD8 + , but not CD4 +, cells is sufficient to induce alopecia in 
tumor-bearing C57BL/6 mice. 
Intralesional injections of steroids in aging C3H/HeJ mice 
suffering from spontaneous alopecia areata resulted in decreased 
intra- and perifollicular lymphocytic infiltrati on and resumption of 
hair g rowth (Sundberg e/ nl, 1994). Based on this observation and 
the es tablished immunosuppressive effects of corticosteroids, Sund-
berg et nl, conclude that lymphocytes are involved in the patho-
genesis of alopecia in these mice. As demonstrated here, intra le-
sional u"ti ection of triamcinolone in areas of immunotherapy-
associated alopecia induced hair regrowth in a similar fashion. It 
should be noted , however, that trauma in murine skin can deli ver 
a potent stimulus for telogen follicl es to ente r into anagen (Argyrus , 
1967 ; Paus and Link, 1988). T hus, the observed hair growth 
induction may not necessa rily re fl ect a specific immunosuppressive 
effect of the inj ected triamcinolone. 
According to Paus el nl, severa l differeilt circuinstances and 
events pred.ispose for th e development of alopecia areata , but none 
of them alone suitlces to indu~e it; only' their coincidence results i n 
hair loss (Paus el nl, 1994a). This hypothesis exp lains not only the 
restriction of alopecia to only a portion of successfully treated 
animals, but also that passive transfer of lymphocytes £i'om treated 
animals either lackin g o r displ aying signs of alopecia are able to 
transmit these phenotypic changes to a similar percentage of nai"ve 
animals. The former observation could also be eas il y explained by 
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the lack of induction of autoreactive lymphocytes. T he latte r 
observation, however, cannot be explained in thi s way. Therefore, 
the initiation of il11l11unotherapy-ulduced alopecia appears to de-
pend on the coin cidence of at least two events: the presence of a 
specifi c lymphocyte population and changes in the skin disclosing a 
target for these cells. Melanogenesis in follicular melanocytes and, 
thereby, the differential expression and activity of melanogenesis-
related proteins, is stri ctly coupled to the hau' cycle (Slominski and 
Paus, 1993). Melanogen esis ceases early in catagen and is com-
pletely absent in telogen. T he finding that nonalopecic treated 
animals can be distinguished £i'om alopecic by the predominance of 
telogen hair follicles in the skin further supports tile hypothesis that 
the presentation of m elanogenesis-related autoantigens is involved 
in this form of immunotherapy-induced alopecia. Future studies 
using experimental anagen induction are likely to give further 
insight into the mechanisms involved in immunotherapy-indu ced 
alopecia (Sl ominski and Paus, 1993; Paus el nl, 1994b). 
In summary, immunotherapy of m elanoma m etastases in 
C57BL/6 mice can be associated with progressive hai r loss, w hich 
shows several characteristics of alopecia area ta. Tlus fo rm of 
alopecia, although m ediated by lymphocytes, depends on further 
predispositions that remain recondite . Our observations not only 
demonstrate the profound and complex immunologic changes 
induced by targeted IL-2 therapy, but also provide intriguing 
evidence to confirm the hypothetical etiolog)' of alopecia areata 
proposed by Paus el nl. (1994a). 
11Ic Ihallkjcssicn 'lnll LecII"'eII alld IHalllle! Perez for Iheir skilled n/ld dedicaled care 
'if lh e allilllais alld A lall MacPheefor excellelll 011 "'ork. IrVcfi mher lI,ish 10 express 
Ollr flpprecintioll jor the slIggestiollS raised by the reJ!ic'IJcI's, ",hich helped to illlpnJllc 
Il, e II wlIIIscript SIIhslOlllially. This ",ork 11'05 sllppo,1cd by OlllSlalldillg [II"esligalor 
Gralll CA 42508 (RAR). J. C. Becker "'as slIpported hy a Iroillillg gralll of Ihe 
Delllsrl", Forsc/lllllgsgclllcillsc/,aji. TI,i5 is Paper 10196-IlvfM FOIII The 5C1ipps 
Research [IIslilllle. 
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